- Launched for 1st time in India, ARTGPT is designed to address queries regarding A.R.T treatments
- Product created to help users get right information about ART treatments and discourage misinformation
Bengaluru, October 29, 2024: SpOvum® is proud to announce the launch of its advanced AI-powered platform, SpOvum ARTPT, aimed at revolutionizing patient interaction in the field of Assisted Reproductive Technology (ART). The ARTGPT leverages natural language processing (NLP) to provide patients with instant, conversational responses 24/7, ensuring continuous support outside clinic hours. The platform offers personalized information based on individual ART-related concerns, drawing from reliable, indexed medical guides to provide fact-based, tailored answers. This is the first time the deep tech startup has ventured into the B2C domain with its products.
The SpOvum ARTGPT enhances accessibility across India by supporting multiple regional languages, including Hindi, Kannada, Tamil, Telugu, Bengali, and many more, fostering inclusivity for a diverse user base. Its mobile-friendly design allows users to access information on any device, ensuring that help is always within reach. The platform simplifies complex medical terminology into patient-friendly language, empowering users to make informed decisions and better prepare for consultations. With stringent data privacy protocols, patient interactions remain confidential and secure.
This is the first time in India’s health tech that a chatbot system has been utilized specifically designed to provide information about A.R.T. Taking pride in this launch, Dr. Ramnath Babu, CEO and Co-Founder, of SpOvum Technologies said “We are thrilled to introduce ARTGPT, the first AI platform of its kind in India’s health tech sector, offering round-the-clock, personalized support for patients. Our ARTGPT pulls information from guides and other reliable ART/infertility documents when asked questions by the users and provides only relevant information. If the query is incorrect or there is no relatable information to be shared, then the product has been designed to not provide any misinformation.”
Looking ahead, SpOvum ARTGPT is set to offer future enhancements such as visual and audio support, further enriching the patient experience. By providing reliable information instantly, the platform reduces patient anxiety, encourages engagement, and promotes a better understanding of treatment options. SpOvum® believes that ARTGPT will transform the patient experience, building trust between patients and healthcare providers while improving mental well-being through accessible, clear, and consistent support.
“By integrating multilingual capabilities and simplifying complex medical information, SpOvum ARTGPT enhances accessibility and empowers patients to make informed decisions about their reproductive health. It also provides consistent, factual information, strengthening trust between patients and healthcare providers. Apart from this, the patient interactions and data are secure and confidential,” said Dr. Santosh Bhargav DB, CTO and Co-founder of SpOvum Technologies.
SpOvum Technologies through the implementation of ARTGPT currently is striving to reach as many people as possible. In the coming days, the startup aims to integrate this with the currently existing A.R.T Dashboard and even phone applications where patient data is in synch with the GPT and information is tailored to respective users, inclusive of daily tracking of medicine intake, ovulations, and other health metrics.
SpOvum ARTGPT Link: https://ask.spovum.ai/
Corporate Comm India (CCI Newswire)
